Viewing data from:

FEMRING

NDA

ESTRADIOL ACETATE | N021367 | MILLICENT MANUFACTURING PR LLC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Femring (2023)

Total Spending

$6.5M

Total Claims

8,715

Beneficiaries

2,894

Avg Cost/Unit

$735.60

Spending Trend

$3.5M(2019)→$5.1M(2020)→$5.6M(2021)→$6.0M(2022)→$6.5M(2023)

YoY Change:+10.2%

5yr CAGR:+11.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

11 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 0.05MG BASE/24HR

RLD

0 patents0 exclusivities▴

INSERT, EXTENDED RELEASE;VAGINAL | Approved: Mar 20, 2003

No patent or exclusivity listings for this strength.

#002 — EQ 0.1MG BASE/24HR

RLD

0 patents0 exclusivities▾

INSERT, EXTENDED RELEASE;VAGINAL | Approved: Mar 20, 2003